Huntington Disease – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Huntington Disease – Drugs In Development, 2023’, provides an overview of the Huntington Disease pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Huntington Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Huntington Disease and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Huntington Disease
- The report reviews pipeline therapeutics for Huntington Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Huntington Disease therapeutics and enlists all their major and minor projects
- The report assesses Huntington Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Huntington Disease
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Huntington Disease
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Huntington Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
AbbVie IncAcademia Sinica
Acahealth Pharma and Biotech Co Ltd
Acen Regenerative Medicine Sci-Tech Co Ltd
Advantx Pharmaceuticals Inc
Aeton Therapeutics Inc
AFFiRiS AG
Alchemab Therapeutics Ltd
Alkermes Plc
Alnylam Pharmaceuticals Inc
Alsonex Pty Ltd
Anima Biotech Inc
ANLBio Co Ltd
Annexon Inc
Annji Pharmaceutical Co Ltd
AOP Health
ArunA Bio Inc
Arvinas Inc
Asdera LLC
Asklepios BioPharmaceutical Inc
Astellas Pharma Inc
Atalanta Therapeutics Inc
Avergen Pharmaceuticals GmbH
Azevan Pharmaceuticals Inc
Beijing Joekai Biotechnology Co Ltd
Biogen Inc
Bionaut Labs Inc
Biorchestra Co Ltd
Blade Therapeutics Inc
BPGbio Inc
BrainStorm Cell Therapeutics Inc
Caladria Therapeutics Inc
Cardiff University
Cellavita Pesquisa Cientifica Ltda
Centre for Drug Design and Discovery
Centre for Genomic Regulation
Ceptur Therapeutics Inc
Chaperone Pharma BV
Chaperone Therapeutics Inc
Children's Hospital of Philadelphia
Chong Kun Dang Pharmaceutical Corp.
Chugai Pharmaceutical Co Ltd
Cleave Therapeutics Inc
Collaborative Medicinal Development LLC
DanPET AB
Eikonoklastes Therapeutics Inc
Epinogen Co Ltd
ethris GmbH
Exicure Inc
Exopharm Ltd
ExoRNA Bioscience Nanjing Co Ltd
F. Hoffmann-La Roche Ltd
Forest Hills Partners Hong Kong Ltd
Fundamental Pharma Gmbh
Gatehouse Bio
Harness Therapeutics
Helmholtz Center Munich German Research Center for Health and Environment GmbH
HuidaGene Therapeutics Co Ltd
Immungenetics AG
Imperial College London
Incisive Genetics Inc
InnoMedica Holding AG
IPS Bio Co Ltd
Janusq LLC
Karolinska Institute
KeifeRx LLC
Krisani Bio Sciences Pvt Ltd
Life Edit Therapeutics Inc
Locanabio Inc
Loqus23 Therapeutics Ltd
Luye Pharma Group Ltd
Malachite Innovations Inc
Massachusetts General Hospital
MassGeneral Institute for Neurodegenerative Disorders
Medesis Pharma SA
Medibiofarma SL
MindImmune Therapeutics Inc
Mitochon Pharmaceuticals Inc
Mitochondria In Motion Inc
Mitoconix Bio Ltd
MitoRx Therapeutics Ltd
MMJ International Holdings Corp
Monash University
National Institute of Neurological Disorders and Stroke
NeuExcell Therapeutics Inc
Neurano Bioscience
Neurimmune Holding AG
Neurodon LLC
NeuroNascent Inc
Neuropore Therapies Inc
NeuroTau Inc
Neuvivo Inc
Nevrox Ltd
New World Laboratories Inc
Nomax Therapeutics Inc
Nuredis Inc
Ophidion Inc
Origami Therapeutics Inc
Oryzon Genomics SA
Oxalys Pharmaceuticals Inc
Paramag Biosciences
Passage Bio Inc
Pfizer Inc
PharmatrophiX Inc
PolyCore Therapeutics LLC
Priavoid GmbH
Prilenia Therapeutics Development Ltd
Primary Peptides Inc
Prime Medicine Inc
ProMIS Neurosciences Inc
ProQR Therapeutics NV
Prous Institute for Biomedical Research SA
PTC Therapeutics Inc
PurMinds NeuroPharma Inc
reMYND NV
ReNeuron Group Plc
Resilio Therapeutics LLC
ResQ Biotech
Retrotope Inc
RIKEN
Rumi Scientific Inc
S M Discovery Group LLC
Sage Therapeutics Inc
Salk Institute for Biological Studies
Sana Biotechnology Inc
Seelos Therapeutics
Inc.
Seneb BioSciences Inc
Shanghai BDgene Therapeutics Co Ltd
Shinkei Therapeutics LLC
Skyhawk Therapeutics Inc
SOLA Biosciences LLC
SOM Biotech SL
Spark Therapeutics Inc
Stealth BioTherapeutics Inc.
Suven Life Sciences Ltd
T3D Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Teitur Trophics ApS
Tel Aviv University
Teva Pharmaceutical Industries Ltd
Trailhead Biosystems Inc
TreeFrog Therapeutics SAS
Triplet Therapeutics Inc
U.S. National Institutes of Health
UCB SA
UniQure NV
University of Alberta
University of California Davis
University of California Irvine
University of Gdansk
University of Kansas
University of Massachusetts Amherst
University of Michigan
University of Strasbourg
University of Wisconsin Madison
Vanqua Bio Inc
VectorY Therapeutics Inc
Vico Therapeutics BV
Vivoryon Therapeutics NV
Voyager Therapeutics Inc
VX3 (DE) LP
Vybion Inc
Washington University in St Louis
Wave Life Sciences Ltd
Weizmann Institute of Science
Woolsey Pharmaceuticals Inc
ZyVersa Therapeutics Inc